US Edition1st patient dosed in trial of PRMT5 inhibitor for glioblastoma
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
1st patient dosed in trial of PRMT5 inhibitor for glioblastoma
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP deletion, including glioblastoma. The trial (NCT06810544) is evaluating the safety, pharmacological properties, and antitumor activity of Tango Therapeutics‘ TNG456 given alone or in combination with abemaciclib, a medication used in the treatment of certain types of breast cancer. TNG456 is being…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
